N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Leukemia, Myeloid, Chronic
Both
Leukemia, Myeloid, Chronic
Trial Information
Inclusion Criteria:
- Patients with Imatinib (Glivec/Gleevec) Resistant or Intolerant CML in Blast Crisis,
Accelerated Phase or Chronic Phase
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Effectiveness
Outcome Time Frame:
overall
Safety Issue:
No
Principal Investigator
Naeem Chaudhri, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
King Faisal Specialist Hospital & Research Centre
Authority:
United States: Institutional Review Board
Study ID:
RAC #2071-008
NCT ID:
NCT00538109
Start Date:
October 2007
Completion Date:
October 2013
Related Keywords:
- Leukemia, Myeloid, Chronic
- CML in Blast Crisis
- Accelerated Phase oe Chronic Phase
- Blast Crisis
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Name | Location |
|---|
